The ROE as of September 2024 (TTM) for MoonLake Immunotherapeutics (MLTX) is -11.05%

According to MoonLake Immunotherapeutics’s latest financial reports and current stock price. The company's current ROE is -11.05%. This represents a change of 305.52% compared to the average of -2.72% of the last 4 quarters.

MoonLake Immunotherapeutics (MLTX) Historical ROE (quarterly & annually)

How has MLTX ROE performed in the past?

The mean historical ROE of MoonLake Immunotherapeutics over the last ten years is 80.35%. The current -11.05% ROE has changed -113.75% with respect to the historical average. Over the past ten years (40 quarters), MLTX's ROE was at its highest in in the December 2021 quarter at 19.08%. The ROE was at its lowest in in the March 2022 quarter at -65.10%.

MoonLake Immunotherapeutics (MLTX) ROE by Quarter and Year

Discovering the peaks and valleys of MoonLake Immunotherapeutics ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

MoonLake Immunotherapeutics (MLTX) Average ROE

How has MLTX ROE performed in the past?

The current ROE of MoonLake Immunotherapeutics (MLTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

MoonLake Immunotherapeutics (MLTX) ROE vs. Peers

How is MLTX’s ROE compared to its peers?

MoonLake Immunotherapeutics’s ROE is less than Terns Pharmaceuticals, Inc. (0%), greater than Day One Biopharmaceuticals, Inc. (-39.58%), greater than Acumen Pharmaceuticals, Inc. (-122.70%), greater than Amylyx Pharmaceuticals, Inc. (-24.63%), greater than Aerovate Therapeutics, Inc. (-46.15%), greater than Enliven Therapeutics, Inc. (-83.65%), greater than Structure Therapeutics Inc. (-29.31%), greater than Compass Therapeutics, Inc. (-20.15%), greater than Ventyx Biosciences, Inc. (-28.67%), greater than Nuvalent, Inc. (-61.43%), greater than Cerevel Therapeutics Holdings, Inc. (-28.83%), greater than Travere Therapeutics, Inc. (-98.94%), greater than Arcellx, Inc. (-102.43%), greater than Akero Therapeutics, Inc. (-12.42%), greater than 89bio, Inc. (-29.56%), greater than Pliant Therapeutics, Inc. (-35.42%), greater than null (-41.05%),

Build a custom stock screener for MoonLake Immunotherapeutics (MLTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MoonLake Immunotherapeutics using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

MoonLake Immunotherapeutics (MLTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like MoonLake Immunotherapeutics or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.